EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Changes in LDL-cholesterol levels following aromatase inhibitor treatment in early postmenopausal breast cancer

Marie Lund, Giulia Corn, Maj-Britt Jensen, Tonny Petersen, Kim Dalhoff, Bent Ejlertsen, Lars Køber, Jan Wohlfahrt, Mads Melbye

European Journal of Epidemiology · 2025-08 · 40 (8) · 937-946

DOI: 10.1007/s10654-025-01228-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Epidemiology, online erschienen am 21.05.2025. Verfasst von Marie Lund und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, 2300, Copenhagen S, Denmark. mxd@ssi.dk. Hauptthemen laut MEDLINE: Breast Neoplasms, Aromatase Inhibitors, Cholesterol, LDL, Postmenopause. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kræftens Bekæmpelse, Fonden til Lægevidenskabens Fremme, Aase og Ejnar Danielsens Fond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is an unsettled concern that treatment with aromatase inhibitors (AIT) may adversely affect lipid-levels. In light of the improved survival of women with breast cancer and increased risk of atherosclerotic cardiovascular disease in older people, unfavorable effects on lipid-levels may represent a significant health concern for this group of patients. We used linked data from nationwide registries, including a clinical breast cancer database with information about allocated and dispensed AIT. Based on these, we investigated changes in plasma lipid-levels (primary outcome: low-density lipoprotein (LDL)-cholesterol, secondary outcomes: high-density lipoprotein (HDL)-cholesterol, total cholesterol, and triglycerides) following AIT in a nationwide cohort of postmenopausal women with early breast cancer, Denmark, 2009–2020. Included women had at least one LDL-cholesterol measurement before and after breast cancer diagnosis. Exposure was allocated and dispensed AIT as compared with not allocated to and no dispensed AIT. Outcome was the adjusted difference in lipid-level-change (from before to after breast cancer diagnosis) according to AIT. Among 10,461 women, there were 22,693 pre-breast cancer LDL-cholesterol measurements and 42,750 post-breast cancer LDL-cholesterol measurements. Overall, 7919 of the women were exposed to AIT and 2542 women were unexposed. For AIT exposed, the LDL-cholesterol-change was − 0.16 mmol/L (mM), and for unexposed, − 0.15 mM, respectively. The corresponding adjusted difference in LDL-cholesterol change for AIT exposed versus unexposed was − 0.03 mM (95% CI − 0.07 to 0.003). We found similar results in analysis of secondary outcomes. This study does not support the concern that AIT adversely affects lipid-levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAromatase InhibitorsCholesterol, LDLPostmenopauseHumansFemaleDenmarkMiddle AgedAgedRegistriesCholesterol, HDLTriglycerides

Stichwörter der Autor:innen

Aromatase inhibitorsEarly breast cancerEndocrine treatmentLDL-cholesterolLipids

Substanzen

Aromatase InhibitorsCholesterol, LDLCholesterol, HDLTriglycerides

Autor:innen und Institutionen

  • Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, 2300, Copenhagen S, Denmark. mxd@ssi.dk.
  • Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital and University of Copenhagen, Copenhagen, Denmark. mxd@ssi.dk.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. mxd@ssi.dk.
  • Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, 2300, Copenhagen S, Denmark.
  • Danish Cancer Institute, Statistics and Data Analysis, Copenhagen, Denmark.
  • Danish Breast Cancer Cooperative Group, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.

Förderung

  • Kræftens Bekæmpelse
  • Fonden til Lægevidenskabens Fremme
  • Aase og Ejnar Danielsens Fond
  • Helsefonden
  • Bispebjerg and Frederiksberg Hospital
  • Læge Sophus Carl Emil Friis og hustru Olga Doris Friis' Legat
  • Statens Serum Institut

Zitieren

APA

Lund, M., Corn, G., Jensen, M. B., Petersen, T., Dalhoff, K., Ejlertsen, B., Køber, L., Wohlfahrt, J., & Melbye, M. (2025). Changes in LDL-cholesterol levels following aromatase inhibitor treatment in early postmenopausal breast cancer. European Journal of Epidemiology, 40(8), 937-946. https://doi.org/10.1007/s10654-025-01228-7

Vancouver

Lund M, Corn G, Jensen MB, Petersen T, Dalhoff K, Ejlertsen B, et al. Changes in LDL-cholesterol levels following aromatase inhibitor treatment in early postmenopausal breast cancer. European Journal of Epidemiology. 2025;40(8):937-946. doi:10.1007/s10654-025-01228-7

BibTeX
@article{Lund2025,
  author = {Lund, Marie and Corn, Giulia and Jensen, Maj-Britt and Petersen, Tonny and Dalhoff, Kim and Ejlertsen, Bent and Køber, Lars and Wohlfahrt, Jan and Melbye, Mads},
  title = {Changes in LDL-cholesterol levels following aromatase inhibitor treatment in early postmenopausal breast cancer},
  journal = {European Journal of Epidemiology},
  year = {2025},
  volume = {40},
  number = {8},
  pages = {937--946},
  doi = {10.1007/s10654-025-01228-7}
}
Kostenlos starten →